ASTRAZENECA CANCER DRUG
Pharma companies announce direct-to-consumer sales and price cuts in US
Several drug makers are now selling medicines directly to Americans. This move follows President Trump's push to reduce prescription drug prices. Companies like AbbVie, AstraZeneca, and Pfizer are offering discounts. A new government website, TrumpRx.gov, is planned for early 2026. Patients will soon have more options to access affordable medications.
AstraZeneca gets regulator's nod to market cancer drug in India
AstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now approved for adult patients with unresectable or metastatic HER2-positive solid tumours. It is the first and only antibody drug conjugate in India with a tumour-agnostic indication. This broadens its potential to help more patients with advanced HER2-positive cancers.
Trump administration targets deals in dozens of industries before midterms
The Trump administration is aggressively pursuing deals across 20-30 critical industries, offering incentives like equity stakes and regulatory relief for concessions such as increased U.S. manufacturing. This "whole-of-government" approach aims to boost domestic production, reduce reliance on China, and secure political wins before the 2026 midterms. This strategy marks a significant departure from traditional American capitalism.
US Pfizer deal powers European health stocks as Trump policy haze clears
European healthcare stocks jumped on Wednesday, mirroring moves in the United States, propelled by a deal between Pfizer and President Donald Trump to lower prescription drug prices in the Medicaid programme in exchange for tariff relief.
AstraZeneca breast cancer medicine slows disease by over six months
AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six months in trials. Camizestrant, combined with other medicines, helped patients live longer without cancer worsening. AstraZeneca hopes this data will establish a new treatment approach. The company anticipates significant sales, though analysts offer more conservative estimates.
AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drug
AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and 150mg in India, citing commercial reasons. The company clarified that the drug was never marketed in India since receiving approval in November 2023 and that the decision is unrelated to safety or efficacy concerns.
- Go To Page 1
Over 3k brands hit pharma mkt, cancer drug tops in sales
India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the top-seller, reflecting a rise in cancer cases. Enhertu, exempted from customs duty, has significantly contributed to AstraZeneca's sales, highlighting the growing demand for innovative cancer treatments.
AstraZeneca India recasts biopharma unit
AstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. The job cuts are part of a strategic restructuring due to loss of patent exclusivity and competition from generic drugs. The company continues to focus on new patented drugs for specialized treatments.
Astrazeneca, Natco Pharma shares rally 4% after GST cut on cancer drugs
In reaction to the update, pharma stocks like Astrazeneca Pharma surged 4.4% to its day’s high of Rs 7,069 on BSE while Fortis Healthcare shares went up by 3% to Rs 563.55 and those of Natco Pharma shot up 2.5% to Rs 1,585.
China detains AstraZeneca staff in data, drug-import probes: Report
"We are aware a small number of our employees in China are under investigation and we have no further information to share at this point," AstraZeneca said in a statement.
AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight
On Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $107.5 million award against AstraZeneca. Pfizer had claimed AstraZeneca's Tagrisso infringed these patents. Judge Kennelly's ruling found the patents lacked sufficient written descriptions and were not reproducible by a skilled scientist. This decision dismisses the damages awarded in May and affects Pfizer’s ongoing patent infringement claims. The case, Wyeth LLC v. AstraZeneca Pharmaceuticals LP, was heard in the District of Delaware.
DCGI orders withdrawal of cancer drug Olaparib for certain treatments
The Drug Controller General of India has requested the withdrawal of AstraZeneca's Olaparib tablets for certain cancer treatments due to potential adverse effects.
Regulator asks state bodies to limit scope of key cancer drug
India's drug regulatory authority has instructed state-level counterparts to mandate manufacturers of Olaparib tablets in 100 mg and 150 mg strengths to cease marketing the cancer medication for patients with advanced ovarian cancer and "gBRCA mutation" (genes associated with tumor suppression), who have undergone three or more rounds of prior chemotherapy treatment.
AstraZeneca to buy fusion for $2 billion
The deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when data from Novartis' treatment showed that the drug extended survival for prostate cancer patients.
AstraZeneca bets on licencing deals, public-private partnerships for India growth
British-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, renal, and metabolic diseases, respiratory and immunology, and rare diseases. The company aims to expand access to its therapies through public-private partnerships, licensing deals, and tiered pricing. AstraZeneca's India business returned to growth in FY23 after a period of plateauing sales, driven by innovative molecules.
AstraZeneca targets 2024 growth but mixed views hit shares
In almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker's pipeline, which includes 13 blockbuster medicines, meaning those that generate more than $1 billion in annual sales.
AstraZeneca, AI biologics firm Absci tie up on cancer drug
Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics
AstraZeneca gets CDSCO nod for drug to treat biliary tract cancer
Drug firm AstraZeneca India on Friday said it has received approval from the domestic drug regulator to market a drug to treat biliary tract cancer (BTC) in the country. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Durvalumab, the drug firm said in a statement.
AstraZeneca India receives DCGI's nod to market drug treating breast cancer
The Drugs Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with early breast cancer, who have previously been treated with neoadjuvant or adjuvant chemotherapy.
Sanofi trial failure ends development of breast cancer treatment amcenestrant
A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly-diagnosed advanced breast cancer, was stopped early because an independent monitoring panel found no signs of it working. "All other studies of amcenestrant, including in early-stage breast cancer (AMEERA-6), will be discontinued," Sanofi said.
AZ to seek India nod for antibody cocktail
Evusheld is a combination of tixagevimab and cilgavimab. The drug received EUA in the US on Thursday for pre-exposure prophylaxis or preventing infection in people aged 12 years and above who are immunocompromised and those who may not mount an adequate immune response to Covid-19 vaccination.
AstraZeneca sells cholesterol drug rights to Grünenthal for $320 million
AstraZeneca, which is among the front-runners in the race to develop a vaccine for the novel coronavirus, has been trying to focus on its cancer drug portfolio as it streamlines its business.
The CEO who capped a $37 billion recovery with AstraZeneca deal
Nakayama decided to reboot Daiichi Sankyo, pivoting toward the more lucrative business of cancer drugs.
High Court rejects AstraZeneca’s diabetes drug plea
The Delhi High Court has dismissed AstraZeneca’s plea to block Hyderabadbased Lee Pharma from making copies of its anti-diabetes drug Onglyza
Good cancer drug data helps AstraZeneca in Pfizer fight
Britain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.
AstraZeneca leaves door ajar to Pfizer, despite hurdles
AstraZeneca's boss said he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's ops into the US co's new three-unit model were addressed.
Major pharma-deals: How anti-cancer drugs are reshaping the pharmaceutical industry
New and considerable optimism over cancer drugs will drive deal-making in pharma over the decade, with companies weak in this segment trying to build up their pipelines, reports ET.
AstraZeneca stock rallies as patent plea for cancer drug rejected
Shares of AstraZeneca were witnessing selling pressure on reports that’s its patent plea on anti-cancer drug Gefitinib were rejected.
Patents appeal board rejects AstraZeneca's plea on cancer drug
Patents appeal board has dismissed AstraZeneca's petition challenging an earlier ruling that refused patent protection for a cancer-fighting drug.
Load More
